Table 2.

Changes in FEV₁ with addition of macrolide

Study	OCS use	Macrolide	n	Duration of macrolide treatment	Pretreatment FEV1 ± SEM	Post treatment FEV1	P
Piacentini et al11	No	Azithromycin	8#	8 weeks	73.5 ± 12.9	74.62 ± 9.76	0.84
Shimizu et al12	No	Roxithromycin	12	8 weeks	81.5 ± 2.2	82.0 ± 3.0	0.64
Zeiger et al13	Yes	TAO	3	6 weeks	67.3 ± 12.4	100 ± 6.0	0.01
Kamada et al14	Yes	TAO	6	12 weeks	80.4 ± 6.5	73.6 ± 6.3	0.00
Eitches et al15	Yes	TAO	11	52 weeks	54 ± 4.8	97 ± 6.5	0.08

Notes: Excluded from this analysis because post treatment FEV₁ values were not recorded;

^#only patients from the treatment group were used in our study to maintain homogeneity as described in the results section.

Abbreviations: TAO, troleandomycin; FEV₁, forced expiratory volume in one second; OCS, oral corticosteroids; SEM, standard error of the mean.